Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
1. Tonmya approved by FDA, first new fibromyalgia treatment in 15 years. 2. Phase 3 studies showed significant fibromyalgia pain reduction with Tonmya. 3. Well-tolerated, supports long-term treatment as a non-opioid option. 4. Commercial availability expected in Q4 2025. 5. Tonix presented promising trial data at PAINWEEK conference 2025.